Development of a high-throughput assay to measure the neutralization capability of anti-cytomegalovirus antibodies

Clinical and Vaccine Immunology

Volumn 20, Issue 4, 2013, Pages 540-550

  Gardner, Thomas J ^a   Bolovan Fritts, Cynthia ^b   Teng, Melissa W ^b   Redmann, Veronika ^a   Kraus, Thomas A ^c   Sperling, Rhoda ^c   Moran, Thomas ^a   Britt, William ^d   Weinberger, Leor S ^b,e,f   Tortorella, Domenico ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b GLADSTONE INSTITUTES   (United States)

^c Gynecology and Reproductive Medicine   (United States)

^d Department of Microbiology ^*  (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS ANTIBODY; HYBRID PROTEIN; IE2 PROTEIN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS PROTEIN; YELLOW FLUORESCENT PROTEIN;

ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; GENE EXPRESSION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IMMEDIATE EARLY GENE; IMMUNE RESPONSE; MEMBRANE FUSION; NONHUMAN; PRIORITY JOURNAL; VIRUS ATTACHMENT; VIRUS NEUTRALIZATION; VIRUS REPLICATION; VIRUS STRAIN;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BACTERIAL PROTEINS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GENES, REPORTER; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LUMINESCENT PROTEINS; NEUTRALIZATION TESTS; PREGNANCY; SENSITIVITY AND SPECIFICITY; STAINING AND LABELING;

EID: 84876466958     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00644-12     Document Type: Article

References (63)

1. Barton ES, White DW, Cathelyn JS, Brett-McClellan KA, Engle M, Diamond MS, Miller VL, Virgin HW, IV. 2007. Herpesvirus latency confers symbiotic protection from bacterial infection. Nature 447:326-329.
2. Noriega V, Redmann V, Gardner T, Tortorella D. 2012. Diverse immune evasion strategies by human cytomegalovirus. Immunol. Res. 54: 140-151.
3. Cherrington JM, Mocarski ES. 1989. Human cytomegalovirus ie1 transactivates the alpha promoter-enhancer via an 18-base-pair repeat element. J. Virol. 63:1435-1440.
4. Meier JL, Stinski MF. 1997. Effect of a modulator deletion on transcription of the human cytomegalovirus major immediate-early genes in infected undifferentiated and differentiated cells. J. Virol. 71:1246-1255.
5. Heider JA, Yu Y, Shenk T, Alwine JC. 2002. Characterization of a human cytomegalovirus with phosphorylation site mutations in the immediateearly 2 protein. J. Virol. 76:928-932.
6. Marchini A, Liu H, Zhu H. 2001. Human cytomegalovirus with IE-2 (UL122) deleted fails to express early lytic genes. J. Virol. 75:1870-1878.
7. White EA, Clark CL, Sanchez V, Spector DH. 2004. Small internal deletions in the human cytomegalovirus IE2 gene result in nonviable recombinant viruses with differential defects in viral gene expression. J. Virol. 78:1817-1830.
8. Reeves M, Murphy J, Greaves R, Fairley J, Brehm A, Sinclair J. 2006. Autorepression of the human cytomegalovirus major immediate-early promoter/enhancer at late times of infection is mediated by the recruitment of chromatin remodeling enzymes by IE86. J. Virol. 80:9998-10009.
9. Glass M, Busche A, Wagner K, Messerle M, Borst EM. 2009. Conditional and reversible disruption of essential herpesvirus proteins. Nat. Methods 6:577-579.
10. Goodrum F, Reeves M, Sinclair J, High K, Shenk T. 2007. Human cytomegalovirus sequences expressed in latently infected individuals promote a latent infection in vitro. Blood 110:937-945.
11. Murphy EA, Streblow DN, Nelson JA, Stinski MF. 2000. The human cytomegalovirus IE86 protein can block cell cycle progression after inducing transition into the S phase of permissive cells. J. Virol. 74:7108-7118.
12. Desai P, Person S. 1998. Incorporation of the green fluorescent protein into the herpes simplex virus type 1 capsid. J. Virol. 72:7563-7568.
13. Straschewski S, Warmer M, Frascaroli G, Hohenberg H, Mertens T, Winkler M. 2010. Human cytomegaloviruses expressing yellow fluorescent fusion proteins-characterization and use in antiviral screening. PLoS One 5:e9174. doi:10.1371/journal.pone.0009174.
14. Ibig-Rehm Y, Gotte M, Gabriel D, Woodhall D, Shea A, Brown NE, Compton T, Feire AL. 2011. High-content screening to distinguish between attachment and post-attachment steps of human cytomegalovirus entry into fibroblasts and epithelial cells. Antiviral Res. 89:246-256.
15. Dal Pozzo F, Andrei G, Daelemans D, Winkler M, Piette J, De Clercq E, Snoeck R. 2008. Fluorescence-based antiviral assay for the evaluation of compounds against vaccinia virus, varicella zoster virus and human cytomegalovirus. J. Virol. Methods 151:66-73.
16. Simpson JA, Chow JC, Baker J, Avdalovic N, Yuan S, Au D, Co MS, Vasquez M, Britt WJ, Coelingh KL. 1993. Neutralizing monoclonal antibodies that distinguish three antigenic sites on human cytomegalovirus glycoprotein H have conformationally distinct binding sites. J. Virol. 67:489-496.
17. Stam NJ, Spits H, Ploegh HL. 1986. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J. Immunol. 137:2299-2306.
18. Bankier AT, Beck S, Bohni R, Brown CM, Cerny R, Chee MS, Hutchi-son CA, III, Kouzarides T, Martignetti JA, Preddie E, Satchwell SC, Tomlinson P, Weston KM, Barrell BG. 1991. The DNA sequence of the human cytomegalovirus genome. DNA Seq. 2:1-12.
19. Yu D, Smith GA, Enquist LW, Shenk T. 2002. Construction of a selfexcisable bacterial artificial chromosome containing the human cytomegalovirus genome and mutagenesis of the diploid TRL/IRL13 gene. J. Virol. 76:2316-2328.
20. Moorman NJ, Cristea IM, Terhune SS, Rout MP, Chait BT, Shenk T. 2008. Human cytomegalovirus protein UL38 inhibits host cell stress responses by antagonizing the tuberous sclerosis protein complex. Cell Host Microbe 3:253-262.
21. Teng MW, Bolovan-Fritts C, Dar RD, Womack A, Simpson ML, Shenk T, Weinberger LS. 2012. An endogenous accelerator for viral gene expression confers a fitness advantage. Cell 151:1569-1580.
22. Yu D, Silva MC, Shenk T. 2003. Functional map of human cytomegalovirus AD169 defined by global mutational analysis. Proc. Natl. Acad. Sci. U. S. A. 100:12396-12401.
23. Warming S, Costantino N, Court DL, Jenkins NA, Copeland NG. 2005. Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res. 33:e36. doi:10.1093/nar/gni035.
24. Cuevas-Bennett C, Shenk T. 2008. Dynamic histone H3 acetylation and methylation at human cytomegalovirus promoters during replication in fibroblasts. J. Virol. 82:9525-9536.
25. Nevels M, Brune W, Shenk T. 2004. SUMOylation of the human cytomegalovirus 72-kilodalton IE1 protein facilitates expression of the 86-kilodalton IE2 protein and promotes viral replication. J. Virol. 78:7803-7812.
26. Bolovan-Fritts C, Wiedeman JA. 2001. Human cytomegalovirus strain Toledo lacks a virus-encoded tropism factor required for infection of aortic endothelial cells. J. Infect. Dis. 184:1252-1261.
27. Noriega VM, Hesse J, Gardner TJ, Besold K, Plachter B, Tortorella D. 2012. Human cytomegalovirus US3 modulates destruction of MHC class I molecules. Mol. Immunol. 51:245-253.
28. Pizzorno MC, Mullen MA, Chang YN, Hayward GS. 1991. The functionally active IE2 immediate-early regulatory protein of human cytomegalovirus is an 80-kilodalton polypeptide that contains two distinct activator domains and a duplicated nuclear localization signal. J. Virol. 65: 3839-3852.
29. Otto SM, Sullivan-Tailyour G, Malone CL, Stinski MF. 1988. Subcellular localization of the major immediate early protein (IE1) of human cytomegalovirus at early times after infection. Virology 162:478-482.
30. Ahn JH, Hayward GS. 1997. The major immediate-early proteins IE1 and IE2 of human cytomegalovirus colocalize with and disrupt PMLassociated nuclear bodies at very early times in infected permissive cells. J. Virol. 71:4599-4613.
31. Schoppel K, Schmidt C, Einsele H, Hebart H, Mach M. 1998. Kinetics of the antibody response against human cytomegalovirus-specific proteins in allogeneic bone marrow transplant recipients. J. Infect. Dis. 178: 1233-1243.
32. Falagas ME, Snydman DR, Ruthazer R, Griffith J, Werner BG, Freeman R, Rohrer R. 1997. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group. Clin. Transplant. 11:432-437.
33. Werner BG, Snydman DR, Freeman R, Rohrer R, Tilney NL, Kirkman RL. 1993. Cytomegalovirus immune globulin for the prevention of primary CMV disease in renal transplant patients: Analysis of usage under treatment IND status. The Treatment IND Study Group. Transplant. Proc. 25:1441-1443.
34. Snydman DR, Werner BG, Meissner HC, Cheeseman SH, Schwab J, Bednarek F, Kennedy JL, Jr, Herschel M, Magno A, Levin MJ, Ron J, Valaes T, Berkman E, McIver J, Leszczynski J, Griffith J, Grady GF. 1995. Use of cytomegalovirus immunoglobulin in multiply transfused premature neonates. Pediatr. Infect. Dis. J. 4:34-40.
35. Grundy JE, Shanley JD, Griffiths PD. 1987. Is cytomegalovirus interstitial pneumonitis in transplant recipients an immunopathological condition? Lancet ii:996-999.
36. Saccoccio FM, Gallagher MK, Adler SP, McVoy MA. 2011. Neutralizing activity of saliva against cytomegalovirus. Clin. Vaccine Immunol. 18: 1536-1542.
37. Hahn G, Revello MG, Patrone M, Percivalle E, Campanini G, Sarasini A, Wagner M, Gallina A, Milanesi G, Koszinowski U, Baldanti F, Gerna G. 2004. Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J. Virol. 78:10023-10033.
38. Patrone M, Secchi M, Fiorina L, Ierardi M, Milanesi G, Gallina A. 2005. Human cytomegalovirus UL130 protein promotes endothelial cell infection through a producer cell modification of the virion. J. Virol. 79:8361-8373.
39. Wang D, Shenk T. 2005. Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism. J. Virol. 79:10330-10338.
40. Ryckman BJ, Jarvis MA, Drummond DD, Nelson JA, Johnson DC. 2006. Human cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low-pH fusion. J. Virol. 80:710-722.
41. Saccoccio FM, Sauer AL, Cui X, Armstrong AE, Habib E-SE, Johnson DC, Ryckman BJ, Klingelhutz AJ, Adler SP, McVoy MA. 2011. Peptides from cytomegalovirus UL130 and UL131 proteins induce high titer antibodies that block viral entry into mucosal epithelial cells. Vaccine 29: 2705-2711.
42. Compton T, Nepomuceno RR, Nowlin DM. 1992. Human cytomegalovirus penetrates host cells by pH-independent fusion at the cell surface. Virology 191:387-395.
43. Britt WJ, Vugler L, Butfiloski EJ, Stephens EB. 1990. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): Use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J. Virol. 64:1079-1085.
44. Gerna G, Sarasini A, Patrone M, Percivalle E, Fiorina L, Campanini G, Gallina A, Baldanti F, Revello MG. 2008. Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection. J. Gen. Virol. 89:853-865.
45. Marshall GS, Li M, Stout GG, Louthan MV, Duliege AM, Burke RL, Hunt LA. 2000. Antibodies to the major linear neutralizing domains of cytomegalovirus glycoprotein B among natural seropositives and CMV subunit vaccine recipients. Viral Immunol. 13:329-341.
46. Sung H, Schleiss MR. 2010. Update on the current status of cytomegalovirus vaccines. Expert Rev. Vaccines 9:1303-1314.
47. Fukui Y, Shindoh K, Yamamoto Y, Koyano S, Kosugi I, Yamaguchi T, Kurane I, Inoue N. 2008. Establishment of a cell-based assay for screening of compounds inhibiting very early events in the cytomegalovirus replication cycle and characterization of a compound identified using the assay. Antimicrob. Agents Chemother. 52:2420-2427.
48. Alford CA, Stagno S, Pass RF, Britt WJ. 1990. Congenital and perinatal cytomegalovirus infections. Rev. Infect. Dis. 12(Suppl 7):S745-S753.
49. Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA. 1992. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N. Engl. J. Med. 326:663-667.
50. Kenneson A, Cannon MJ. 2007. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev. Med. Virol. 17:253-276.
51. Grangeot-Keros L, Mayaux MJ, Lebon P, Freymuth F, Eugene G, Stricker R, Dussaix E. 1997. Value of cytomegalovirus (CMV) IgG avidity index for the diagnosis of primary CMV infection in pregnant women. J. Infect. Dis. 175:944-946.
52. Lazzarotto T, Spezzacatena P, Pradelli P, Abate DA, Varani S, Landini MP. 1997. Avidity of immunoglobulinGdirected against human cytomegalovirus during primary and secondary infections in immunocompetent and immunocompromised subjects. Clin. Diagn. Lab. Immunol. 4:469-473.
53. Eggers M, Bader U, Enders G. 2000. Combination of microneutralization and avidity assays: Improved diagnosis of recent primary human cytomegalovirus infection in single serum sample of second trimester pregnancy. J. Med. Virol. 60:324-330.
54. Mace M, Sissoeff L, Rudent A, Grangeot-Keros L. 2004. A serological testing algorithm for the diagnosis of primary CMV infection in pregnant women. Prenat. Diagn. 24:861-863.
55. Kraus TA, Engel SM, Sperling RS, Kellerman L, Lo Y, Wallenstein S, Escribese MM, Garrido JL, Singh T, Loubeau M, Moran TM. 2012. Characterizing the pregnancy immune phenotype: Results of the viral immunity and pregnancy (VIP) study. J. Clin. Immunol. 32:300-311.
56. Soderberg-Naucler C. 2006. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer? J. Intern. Med. 259:219-246.
57. Craighead JE, Kanich RE, Almeida JD. 1972. Nonviral microbodies with viral antigenicity produced in cytomegalovirus-infected cells. J. Virol. 10: 766-775.
58. Fiala M, Honess RW, Heiner DC, Heine JW, Jr, Murnane J, Wallace R, Guze LB. 1976. Cytomegalovirus proteins. I. Polypeptides of virions and dense bodies. J. Virol. 19:243-254.
59. Irmiere A, Gibson W. 1983. Isolation and characterization of a noninfectious virion-like particle released from cells infected with human strains of cytomegalovirus. Virology 130:118-133.
60. Sarov I, Abady I. 1975. The morphogenesis of human cytomegalovirus. Isolation and polypeptide characterization of cytomegalovirions and dense bodies. Virology 66:464-473.
61. Forghani B, Schmidt NJ. 1980. Humoral immune response to virions and dense bodies of human cytomegalovirus determined by enzyme immunofluorescence assay. J. Med. Virol. 6:119-127.
62. Pepperl S, Munster J, Mach M, Harris JR, Plachter B. 2000. Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression. J. Virol. 74:6132-6146.
63. Klein M, Schoppel K, Amvrossiadis N, Mach M. 1999. Strain-specific neutralization of human cytomegalovirus isolates by human sera. J. Virol. 73:878-886.